- Issuer ticker
-
CLDX
- Reported as of
-
15 Jun 2023
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
20 Jun 2023, 16:19:39 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Samuel B. Martin, attorney-in-fact for Richard M. Wright
Key filing fact
Richard M. Wright filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 20 Jun 2023.
Key facts
- This page summarizes Richard M. Wright's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Jun 2023, 16:19.
Change
- Previous filing in this sequence was filed on 17 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Incentive Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
-
$0.000000
- Shares after
- 45,000
- Date
- 15 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $36.87
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Explanation of responses
2 footnotes